Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Savolitinib vs Sunitinib in MET-Driven Papillary Renal Cell Carcinoma
NCT03091192Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Jul 2017
- Primary completion
- Aug 2019
- Modality
- Small Molecules
- Countries
- 7
01
Overview
A Phase 3 trial of savolitinib in papillary renal cell carcinoma (PRCC), sponsored by AstraZeneca. Started Jul 2017; status: active, not recruiting.
02
Drugs
savolitinib
03
Conditions
papillary renal cell carcinoma (PRCC)
Beyond the preview
Go deeper on NCT03091192.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03091192.